BJBeatriz Jiménez-Matías

Beatriz Jiménez-Matías

*This is an algorithmically generated author record based on publicly available information.

Beatriz Jiménez-Matías has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Aida Falgas

    Josep Carreras Leukaemia Research Institute, Barcelona, Spain

    1 shared publication
  • Alba Martinez-Moreno

    Josep Carreras Leukaemia Research Institute, Barcelona, Spain

    1 shared publication
  • Alba Pérez-Pons

    Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), University of Salamanca, Salamanca, Spain

    1 shared publication
  • Alberto Orfao

    Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), University of Salamanca, Salamanca, Spain

    1 shared publication
  • Anaïs Jiménez-Reinoso

    Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain

    1 shared publication
  • Belén Blanco

    Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain

    1 shared publication

Latest Publications

  • Hemizygous Amplification and Sanger Sequencing of HLA‐B*35:433 From an Umbilical‐Cord Blood Sample

    by Beatriz Jiménez‐Matías, Sofía Garrido, Míriam García‐Jiménez, Carlos Vilches, Francisco Serrano‐Martínez

    HLA‐B*35:433 was fully characterised using sequence‐based typing after haplo‐specific amplification.


  • Open Access

    CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression

    by Javier Arroyo-Ródenas, Aida Falgas, Laura Díez-Alonso, Alba Martinez-Moreno, Heleia Roca-Ho, Francisco J. Gil-Etayo, Alba Pérez-Pons, Óscar Aguilar-Sopeña, Miriam Velasco-Sidro, Marina Gómez-Rosel, et al.

    Background CD19-directed cancer immunotherapies, based on engineered T cells bearing chimeric antigen receptors (CARs, CAR-T cells) or the systemic administration of bispecific T cell-engaging (TCE) antibodies, have shown impressive clinical responses in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, more than half of patients relapse after CAR-T or TCE therapy, with antigen escape or lineage switching accounting for one-third of disease recurrences. To minimize tumor escape, dual-targeting CAR-T cell therapies simultaneously targeting CD19 and CD22 have been developed and validated both preclinically and clinically. Methods We have generated the first dual-targeting strategy for B-cell malignancies based on CD22 CAR-T cells secreting an anti-CD19 TCE antibody (CAR-STAb-T) and conducted a comprehensive preclinical characterization comparing its therapeutic potential in B-ALL with that of previously validated dual-targeting CD19/CD22 tandem CAR cells (TanCAR-T cells) and co-administration of two single-targeting CD19 and CD22 CAR-T cells (pooled CAR-T cells). Results We demonstrate that CAR-STAb-T cells efficiently redirect bystander T cells, resulting in higher cytotoxicity of B-ALL cells than dual-targeting CAR-T cells at limiting effector:target ratios. Furthermore, when antigen loss was replicated in a heterogeneous B-ALL cell model, CAR-STAb T cells induced more potent and effective cytotoxic responses than dual-targeting CAR-T cells in both short- and long-term co-culture assays, reducing the risk of CD19-positive leukemia escape. In vivo, CAR-STAb-T cells also controlled leukemia progression more efficiently than dual-targeting CAR-T cells in patient-derived xenograft mouse models under T cell-limiting conditions. Conclusions CD22 CAR-T cells secreting CD19 T-cell engagers show an enhanced control of B-ALL progression compared with CD19/CD22 dual CAR-based therapies, supporting their potential for clinical testing.